Summary
Thirty-eight pretreated patients with primarily resistant [6] or relapsed [32] small-cell lung cancer were treated with a combination of vindesine (3–4 mg/m2) and cisplatin (60–100 mg/m2). Eight patients responded to this therapy with three (8%) complete and five (13%) partial remissions. Minor responses were noted in 12 (32%) additional patients. Chemotherapeutic response was rare in regions of prior irradiation. In the complete remission group survival from start of vindesine/cisplatin therapy lasted 61, 48 and 38 weeks, respectively. In the “less-than-complete-remission” group median survival was 12 weeks. Nausea and vomiting were the prominent side-effects, while only mild to moderate myelosuppression was noticed in most cases. The vindesine/cisplatin combination showed significant activity in heavily pretreated small-cell lung carcinoma. However, the remission rates remain low in this unfavourable condition, which might be due to pronounced chemotherapeutic resistance in previously irradiated areas.
Similar content being viewed by others
References
Aisner J, Whitacre M, Van Echo DA, Wiernik PH (1982) Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations. Cancer Treat Rep 66:221–230
Aroney RS, Bell DR, Chan WK, Dalley DN, Levi JA (1982) Alternating non-cross-resistant combination chemotherapy for small cell anaplastic carcinoma of the lung. Cancer 49:2449–2454
Bhuchar VK, Lanzotti VJ (1982) High-dose cisplatin for lung cancer. Cancer Treat Rep 66:375–376
Cavalli F, Goldhirsch A, Siegenthaler P, Kaplan S, Beer M (1980) Phase-II study with cisdichlorodiammineplatinum (II) in small cell anaplastic bronchogenic carcinoma. Eur J Cancer 16:617–621
Chiuten DF, Booser DJ, Murphy W, Spitzer G, Umsawasdi T, Bodey GP, Valdivieso M (1982) Response of refractory small cell bronchogenic carcinoma to Vindesine and cis-Platinum. III. World Conference on Lung Cancer, Tokyo, Abstr 216, p 159
Cohen MH, Ihde DC, Bunn PA jr, Fossieck BE jr, Matthews MJ, Shackney SE, Johnston-Early A, Makuch R, Minne JD (1979) Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Cancer Treat Rep 63:163–170
Creech RH, Stanley K, Vogl SE, Ettinger DS, Bonomi PD, Salazar O (1982) Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578). Cancer Treat Rep 66:1417–1419
DeJager R, Longeval E, Klastersky J (1980) High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: a phase II clinical trial of the EORTC Lung Cancer Working Party (Belgium). Cancer Treat Rep 64:1341–1346
Evans WK, Osoba D, Feld R, Shepherd FA (1982) VP-16 alone and in combination with Cisplatin (P) for relapse in small cell lung cancer (SCLC). III. World Conference on Lung Cancer, Tokyo, Abstr 218, p 160
Fox RM, Woods RL, Brodie GN, Tattersall MHN (1980) A randomized study: small cell anaplastic lung cancer treated by combination chemotherapy and adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 6:1083–1085
Greco FA, Richardson RL, Snell JD, Stroup SL, Oldham RK (1979a) Small cell lung cancer. Complete remission and improved survival. Am J Med 66:625–630
Greco FA, Einhorn LH, Hande KR, Oldham RK (1979b) Phase II studies in resistant small cell lung cancer. Proc Am Assoc Cancer Res Am Soc Clin Oncol 19:28
Harper PG, Souhami RL, Spiro SG, Geddes DM, Guimaraes M, Fearon F, Smyth JF (1982) Tumor size, response rate, and prognosis in small cell carcinoma of the bronchus treated by combination chemotherapy. Cancer Treat Rep 66:463–470
Hill BT, Whelan RDH (1982) Establishment of vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivities. Cancer Chemother Pharmacol 8:163–169
Holoye PY, Libnoch JA, Byhardt RW, Cox JD (1982) Integration of chemotherapy and radiation therapy for small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 8:1593–1596
Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. Cancer 1:634–656
Kies MS, Mira J, Chen T, Livingston RB (1982) Value of chest radiation (RT) in limited small cell lung cancer after chemotherapy (CT)-induced complete disease remission. Proc Am Soc Clin Oncol 1:141
Levenson RM jr, Ihde DC, Huberman MS, Cohen MH, Bunn PA, Minna JD (1981) Phase II trial of cisplatin in small celll carcinoma of the lung. Cancer Treat Rep 65:905–907
Livingston RB, Moore TN, Heilbrun L, Bottomley R, Lehane D, Rivkin SE, Thigpen T (1978) Small-cell carcinoma of the lung: combined chemotherapy and radiation. A Southwest Oncology Group study. Ann Int Med 88:194–199
Natale RB, Gralla RJ, Wittes RE (1981) Phase II trial of vindesine in patients with small cell lung carcinoma. Cancer Treat Rep 65:129–131
Niederle N, Krischke W, Schulz U, Schmidt CG, Seeber S (1982a) Untersuchungen zur kurzzeitigen Induktions- und zyklischen Erhaltungstherapie beim inoperablen kleinzelligen Bronchialkarzinom. Klin Wochenschr 60:829–838
Niederle N, Krischke W, Bremer K, Schmidt CG, Seeber S (1982b) Small-cell bronchogenic carcinoma — primary and relapse therapy with etoposide (VP-16), methotrexate and CCNU. Cancer Treat Rev (Suppl A) 9:101–105
Østerlind K, Dombernowsky P, Sørensen PG, Hansen HH (1981) Vindesine in the treatment of small cell anaplastic bronchogenic carcinoma. Cancer Treat Rep 65:245–248
Peschel RE, Kapp DS, Carter D, Knowlton A (1981) Long term survivors with small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 7:1545–1548
Poplin EA, Aisner J, Van Echo DA, Whitacre M, Wiernik PH (1982) CCNU, vincristine, methotrexate, and procarbazine treatment of relapsed small cell lung carcinoma. Cancer Treat Rep 66:1557–1559
Rosenfelt FP, Sikic BI, Daniels JR, Rosenbloom BE (1980) Phase II evaluation of cis-diamminedichloroplatinum (DDP) in small cell carcinoma of the lung (SCC). Proc Am Assoc Cancer Res Am Soc Clin Oncol 20:449
Seeber S, Niederle N, Schilcher RB, Schmidt CG (1980) Adriamycin, Cyclophosphamid und Vincristin (“ACO”) beim kleinzelligen Bronchialkarzinom. Verlaufsanalyse und Langzeitergebnisse. Onkologie 3:5–11
Seeber S, Osieka R, Schmidt CG, Achterrath W, Crooke ST (1982) In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II). Cancer Res 42:4719–4725
Sierocki JS, Golbey RB, Wittes RE (1978) Combination chemotherapy for small cell carcinoma of the lung (SCCL) Proc Am Ass Cancer Res Am Soc Clin Oncol 19:352
Thatcher N, Hunter RD, Jegarajah S, Barber PV, Carroll KB, Wilkinson PM, Crowther D (1982) 11-week course of sequential methotrexate, thoracic irradiation, and moderate-dose cyclophosphamide for “limited”-stage small-cell bronchogenic carcinoma. Lancet 1:1040–1043
Valdivieso M, Bedikian AY, Bodey GP, Freireich EJ (1984) Broad phase II study of vindesine. Cancer Treat Rep 65:877–879
Witte RS, Chang AYC, Tormey DC, Earhart RH, Borden EC, Ramirez G, Hogan T, Bryan GT (1982) Vindesine sulfate (VND): a phase II trial in small cell bronchogenic carcinoma (SCCL). Proc Am Soc Clin Oncol 1:143
Young JA, Dillman RO, Seagren SL, Taetle R, Rentschler RE, Lea JW jr, Lehar TJ, Green MR, Stanton W, Mendelsohn J, Royston I (1982) Non-cross-resistant chemotherapy and consolidation radiotherapy for small cell carcinoma of the lung. Cancer Treat Rep 66:1399–1401
Author information
Authors and Affiliations
Additional information
Supported by BMFT, Bonn: „Arzneimittelentwicklung undtestung für die Krebstherapie“
Rights and permissions
About this article
Cite this article
Niederle, N., Schütte, J., Krischke, W. et al. Vindesine/Cisplatin chemotherapy in relapsed or primarily resistant small-cell carcinoma of the lung. Klin Wochenschr 62, 783–786 (1984). https://doi.org/10.1007/BF01721778
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01721778